What Is NAD+?
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in all living cells. It exists in two primary forms: NAD+ (oxidized) and NADH (reduced), which cycle between states as part of redox reactions central to cellular metabolism. NAD+ participates in more than 400 enzymatic reactions, making it one of the most broadly involved molecules in cellular biochemistry.
Research interest in NAD+ has grown substantially over the past two decades, driven by findings linking NAD+ levels to mitochondrial function, DNA repair capacity, sirtuin enzyme activity, and the biology of cellular aging. Studies have demonstrated that NAD+ concentrations decline with age in multiple tissues, a phenomenon that has become a central focus of longevity and metabolic research.
NAD+ in Energy Metabolism
NAD+ serves as an electron carrier in the mitochondrial electron transport chain, shuttling electrons derived from glycolysis and the citric acid cycle to complex I of the chain. This process drives ATP synthesis, the primary currency of cellular energy. Without adequate NAD+, oxidative phosphorylation and ATP production are impaired, with downstream consequences for cellular function across high-energy-demand tissues including skeletal muscle, neurons, and cardiac tissue.
Research has established a strong mechanistic link between NAD+ availability and mitochondrial biogenesis through the SIRT1/PGC-1α axis. Studies in rodent models have demonstrated that restoring NAD+ levels activates SIRT1, a NAD+-dependent deacetylase, which in turn activates PGC-1α, a master regulator of mitochondrial biogenesis and oxidative metabolism.
Sirtuins and the NAD+-Longevity Connection
Sirtuins are a family of seven NAD+-dependent deacylases (SIRT1–SIRT7) that regulate a wide range of biological processes including gene expression, stress responses, and metabolic homeostasis. Because sirtuin enzymatic activity is directly dependent on NAD+ availability, the age-related decline in NAD+ has been proposed as a mechanism linking metabolic decline to reduced sirtuin activity.
Research by Verdin (2015) published in Science provided a comprehensive review of sirtuins as potential mediators of aging biology, highlighting NAD+ metabolism as a key regulatory node. Studies in model organisms from yeast to mice have demonstrated that increasing NAD+ availability, either directly or through precursor supplementation, activates sirtuin pathways and has been associated with extended lifespan and improved metabolic parameters in these models.
NAD+ and DNA Repair
PARP enzymes (poly ADP-ribose polymerases) are a family of nuclear proteins that play a central role in the DNA damage response. PARP activation following DNA strand breaks consumes NAD+ as a substrate, with each repair cycle degrading multiple NAD+ molecules. Research by Rajman, Chwalek, and Sinclair (2018) in Cell Metabolism demonstrated that the age-related accumulation of DNA damage, combined with sustained PARP activation, may contribute significantly to the observed decline in cellular NAD+ levels over time, creating a feedback loop that impairs the cell's ability to maintain genomic integrity.
NAD+ Precursors: NMN and NR
Because direct NAD+ supplementation faces bioavailability challenges at the cellular level, research has focused on precursor molecules that can enter cells more readily and be converted to NAD+ intracellularly. The two most extensively studied precursors are:
- NMN (Nicotinamide Mononucleotide): Studies in aged mice by Mills et al. (2016) in Cell Metabolism demonstrated that oral NMN supplementation suppressed age-associated physiological decline, improved energy metabolism, and enhanced mitochondrial function. Human pharmacokinetic data has since confirmed that NMN is efficiently absorbed and converted to NAD+ in multiple tissues.
- NR (Nicotinamide Riboside): Elhassan et al. (2019) demonstrated in a human trial published in Cell Reports Medicine that NR supplementation increased NAD+ levels in skeletal muscle and peripheral blood mononuclear cells. Multiple subsequent human studies have confirmed NAD+ augmentation via NR, though the physiological significance of these increases in humans continues to be evaluated.
Neurological Research
The brain has high metabolic demand and relatively limited antioxidant capacity, making it particularly vulnerable to NAD+ depletion. Research has examined NAD+ in the context of neurodegeneration, with studies demonstrating that NAD+ repletion in mouse models of Alzheimer's disease (using the 3xTg-AD model) improved cognitive performance and reduced amyloid pathology. The proposed mechanisms involve both improved mitochondrial function and enhanced sirtuin-mediated neuroprotective signaling.
Current Research Status
NAD+ precursor research has advanced to human clinical trials at several academic institutions, including studies at the Sinclair Lab at Harvard, Washington University, and others. While early human data confirm that NAD+ augmentation is achievable through precursor supplementation, the clinical significance and optimal protocols for various research applications continue to be characterized. Direct NAD+ infusion has also been studied in pilot human settings, though standardized protocols have not been established.
Selected References
- Verdin E. (2015). NAD+ in aging, metabolism, and neurodegeneration. Science, 350(6265):1208–1213.
- Rajman L, Chwalek K, Sinclair DA. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism, 27(3):529–547.
- Mills KF, et al. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism, 24(6):795–806.
- Elhassan YS, et al. (2019). Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports, 28(7):1717–1728.
- Hou Y, et al. (2021). NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS–STING. PNAS, 118(37):e2011226118.